UK cancer vaccine advance – Recognising and realising opportunities
Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes have highlighted the accelerated pace of vaccine development and deployment. Leveraging this momentum, attention has shifted to cancer vaccines and personalised cancer vac...
Saved in:
| Main Authors: | Charles Craddock, Philip Earwaker, Matthew Fittall, Elisa Fontana, Divya Ganesh, Marco Gerlinger, Qamar Ghafoor, Robert P Jones, Victoria Kunene, Lennard Lee, Rebecca Lee, Siow-Ming Lee, Mark Linch, Martin Little, Justin Liu, Hayley McKenzie, Russell Petty, David J Pinato, Thomas Powles, Andrew Protheroe, Tim Robinson, Paul J Ross, Kai Keen Shiu, James Spicer, Stefan Symeonides, Michael Tilby, Dale Vimalachandran, Jenny Y Wang, Andrew Wardley, Helen Winter |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-01-01
|
| Series: | Cambridge Prisms: Precision Medicine |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S275261432400005X/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bridging the gap: The future of biosimilars regulations
by: Anan S. Jarab, et al.
Published: (2024-12-01) -
Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme
by: Yuanyuan Zhu, et al.
Published: (2025-06-01) -
Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
by: Xuhua Huang, et al.
Published: (2024-12-01) -
POTENTIAL ANALYSIS OF HERBAL ACTIVE COMPOUNDS AS IMMUNOTHERAPEUTIC AGENTS AGAINST CLTA-4 RECEPTOR THROUGH IN-SILICO
by: Darlene Nabila Zetta, et al.
Published: (2025-04-01) -
Characterization of a Potential Therapeutic Anti-Canine PD-1 Single Domain Antibody Produced in Yeast
by: Kartikeya Vijayasimha, et al.
Published: (2025-07-01)